Adaptive Biotechnologies

Company snapshot

Adaptive Biotechnologies is a pioneer and leader in immune-driven medicine that aims to improve people’s lives by learning from the wisdom of their adaptive immune systems. Adaptive’s proprietary immune profiling platform reveals and translates insights from our adaptive immune systems with unprecedented scale and precision. Working with drug developers, clinicians and academic researchers, we are

• 19 active pipeline program(s) linked via ClinicalTrials.gov.
• 12 US patent(s) indexed to this assignee profile.
• 19 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Adaptive Biotechnologies. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for Adaptive Biotechnologies.

1. Jun 8, 2026 Clinical update

   GCAR-7213 — Phase 3

2. Jun 8, 2026 Clinical update

   Venetoclax monotherapy — Phase 2

3. Jun 8, 2026 Clinical update

   Phage Therapy — Phase 2

4. Jun 8, 2026 Clinical update

   Mosunetuzumab — Phase 2

5. Jun 8, 2026 Clinical update

   Intervention B Vilazodone Hydrochloride (HCl) — Phase 2

View all clinical trial activity →

• What is Adaptive Biotechnologies?

  Adaptive Biotechnologies is a biotech organization headquartered in Seattle, USA. It trades on NYSE under ticker ADPT. Primary therapeutic focus areas include Post Traumatic Stress Disorder, Prosthetic Joint Infection, Oncology - Glioblastoma (GBM), Chronic Tonal Tinnitus, Tinnit

• Is Adaptive Biotechnologies publicly traded?

  Yes. Adaptive Biotechnologies is listed with ticker ADPT on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Adaptive Biotechnologies develop or market?

  We link 23 drug profile(s) where Adaptive Biotechnologies is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/adaptive-biotechnologies-corp#company-drugs.

• What are the latest developments for Adaptive Biotechnologies?

  In the last 12 months our linked public records show 19 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Adaptive Biotechnologies focus on?

  Adaptive Biotechnologies focuses on Post Traumatic Stress Disorder, Prosthetic Joint Infection, Oncology - Glioblastoma (GBM) based on our analysis of their pipeline programs and drug development activities.